Kyowa Kirin Co., Ltd. has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for istradefylline as an… read more.
Asthma afflicts more than 300 million people worldwide. The most severe manifestation, known as non-Th2, or non-atopic childhood asthma, represents the majority of the cases, greater than 85%,… read more.
The FDA has granted approval to Octapharma USA for Octagam 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment… read more.
For people with diabetes who are insulin dependent, glycemic control is a full-time job. But what if their medication could do the work for them — an insulin… read more.
Rates of the very rare clotting disorder, thrombosis with thrombocytopenia syndrome (TTS), following a second dose of Vaxzevria are comparable to the background rate in an unvaccinated population… read more.
Acne is often viewed as a disease of adolescence but for many women it persists into adulthood. In a qualitative study of 50 adult women with acne, participants… read more.
New research carried out under the auspices of the Canadian Multicentre Osteoporosis Study (CaMos) has found that cognitive decline is linked with accelerated bone loss and an increased… read more.
BeiGene, Ltd. a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced that Brukinsa (zanubrutinib) has… read more.
Investigations carried out at the La Jolla institute for Immunology (LJI) Show that the combination of vitamin C and TET proteins are essential for the proper function of… read more.
It’s so commonplace we barely give it a second thought, but human brains seem hardwired to see human faces where there are none — in objects as varied… read more.
Levels of omega-3 fatty acids in the blood are as good a predictor of mortality from any cause as smoking, according to a study involving the Hospital del… read more.
Genentech, a member of the Roche Group announced results from the final analysis of the Phase IIIb STASEY study , which confirm the favorable safety profile of Hemlibra… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
